
HK inno.N to begin phase 3 trial of obesity drug in 300 patients in Korea
HK inno.N said it has received approval from the Ministry of Food and Drug Safety to begin a phase 3 clinical trial of its investigational obesity treatment, IN-B00009 (ingredient: ecnoglutide), a glucagon-like peptide-1 receptor agonist (GLP-1 RA). HK …